ClinicalTrials.gg
TerminatedNCT00534313Updated Aug 1, 2012Results posted

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

A Phase 2 interventional study of Abatacept and Placebo in Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Terminated at 44 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-01.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of efficacy with respect to skin-related lesions in the short-term phase

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
191
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 3 of them phase 3. Arthritis, Psoriatic · Bristol-Myers Squibb.

Started
2007
the only one that year
Phase 2
2 of 12
none open now
Registered
1st of 12
by date

Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, this one is the only one that started in 2007, is one of 2 in phase 2, and was the 1st registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

1 of the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb is open now. Recruiting first, the newest first:

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Meeting classification criteria for psoriatic arthritis for a duration of disease of at least 3 months
  • Prior failure (inefficacy or intolerance) of therapy with disease-modifying antirheumatic drugs; if patient had prior failure of methotrexate, he or she must have been taking at least 15 mg per week for at least 2 months
  • If recent failure(inefficacy or intolerance) of a tumor necrosis factor α-blockade compound, participant must be washed out prior to first dose: 56 days for infliximab and 28 days for etanercept and adalimumab
  • Disease activity as defined by a tender joint count of ≥3, swollen joint count of ≥3, and clinically detectable synovitis at screening and Day 01 (prior to infusion)
  • Active psoriasis with a qualifying target lesion ≥2 cm in diameter
  • Able to undergo magnetic resonance imaging
  • Use of appropriate by women of child bearing potential ()

Key Exclusion Criteria:

  • WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 10 weeks after the last dose of product
  • Women who are pregnant or breastfeeding or who plan to become pregnant or to start breastfeeding during the duration of the study
  • Women with a positive pregnancy test on enrollment or prior to investigational product administration.
  • Participants scheduled for or anticipating joint replacement surgery.
  • Those with a recent history of drug or alcohol abuse
  • Concomitant illness that in the investigator's opinion is likely to require systemic glucocorticosteroid therapy during the study (for example: moderate to severe asthma)
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, pulmonary, cardiac, neurologic, ophthalmologic, or cerebral disease.
  • Unwillingness or inability to undergo screening based on current local or country guidelines/standards to evaluate the presence of cancer
  • Cancer within the last 5 years
  • Current or signs of possible malignancy detected by screening procedures for which the workup to exclude malignancy has not been completed or malignancy cannot be excluded
  • At risk for or history (within 3 years) of tuberculosis
  • Any serious bacterial infection within the last 3 months, not treated and resolved with antibiotics, or any chronic bacterial infection (such as, but not limited to, chronic pyelonephritis, osteomyelitis, and bronchiectasis)
  • Evidence of active or latent bacterial or viral infection infections at the time of potential enrollment
  • Herpes zoster or cytomegalovirus resolving less than 2 months prior to signing
  • Receipt of any within 3 months of the anticipated first dose of study medication or anticipation of the need for a live vaccine at any time during and for 3 months after the duration of the study

Long-term period participants: Must have met eligibility criteria for short-term period and completed short-term (24-week) period of the study

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
191 participants (actual)

Study arms

  • Active comparator
    Abatacept (30/10)

    Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for dosing on Days 1 and 15 followed by fixed dosing as per rheumatoid arthritis label (participants weighing \<60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \>100 kg received 1000 mg) thereafter.

    Drug: Abatacept

  • Active comparator
    Abatacept (10/10)

    Abatacept (10 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141 in the double-blind period and continued for next 18 months in the open-label period till Day 729. All participants received a dose based on their screening visit weight as per rheumatoid arthritis label (participants weighing \<60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \>100 kg received 1000 mg).

    Drug: Abatacept

  • Active comparator
    Abatacept (3/3)

    Abatacept (3 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants.

    Drug: Abatacept

  • Placebo comparator
    Placebo

    Placebo solution (5% dextrose in water for injection, 0.9% sodium chloride injection) by iv infusion was administered on Days 1, 15, and 29 and every 28 days thereafter till Day 141.

    Drug: Placebo

Interventions

  • Solution, intravenous, monthly, short-term = 24 weeks (6 months)

    Also known as: Orencia, BMS-188667

  • DrugPlacebo

    Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)

06

What researchers measure

Primary outcomes

  1. Long-term Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Drug-related AEs, AEs Leading to Discontinuation, and AEs of Interest

    Presp=prespecified; acute= ≤1 hour after start of infusion; periinfusional= ≤24 hours after start of infusion. AE=any new unfavorable symptom or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=an unfavorable medical event that at any dose results in death, significant disability, drug dependency/abuse, hospitalization or prolonged hospitalization; is life-threatening, an important medical event, or a congenital anomaly/birth defect. Drug-related=possibly, probably, or certainly related and of unknown relationship to study drug.

    Time frame: From Day 169 to Day 729

  2. Short-term Period: Number of Participants With ACR 20 Response at Day 169

    An ACR 20 responder was a participant who had a reduction of 20% or more from baseline in scores for both tender and swollen joints and had a reduction from baseline of 20% or more in 3 out of the following 5 assessments: participant's assessment of disease activity, participant's global assessment of disease activity, investigator's global assessment of disease activity, participant's assessment of physical function by HAQ-DI, and Disease Activity Score 28-C reactive protein.

    Time frame: At Day 169 from Baseline

Secondary outcomes

  1. Long-term Period: Percentage of Participants Achieving American College of Rheumatology (ACR) 20, ACR 50, ACR 70, ACR 90 Responses at Days 365 and 729

    An ACR 20 (50, 70, 90) responder was a participant whose counts for both tender and swollen joints was reduced by 20% (50%, 70%, 90%, respectively) or more from baseline and who had a reduction of 20% (50%, 70%, 90%, respectively) or more from baseline in 3 of the following assessments: participant's assessment of disease activity, participant's global assessment of disease activity, Investigators Global Response, participant's assessment of physical function by Health Assessment Questionnaire Disability Index, and Disease Activity Score 28 based on C-reactive protein.

    Time frame: At Days 365 and 729 from Baseline

  2. Long-term Period: Number of Participants With an Investigators Global Assessment (IGA) Score of Clear or Almost Clear at Days 365 and 729

    IGA score indicates lesion induration, scaling, and erythema: 0=clear (no signs of plaque psoriasis except for residual discoloration); 1=almost clear (just perceptible erythema, no induration to very slightly elevated above normal skin levels, limited amount of very fine scaling); 2=mild disease (mild erythema, mild induration, mainly fine scaling predominates); 3=moderate disease (moderate erythema \[most plaques are red\], moderate induration and/or coarse scale predominates); 4=severe (severe erythema, marked to very marked elevation of lesions, coarse thick scale predominates).

    Time frame: From Day 169 to Days 365 and 729

  3. Long-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Days 365 and 729

    Target lesion score is a measurement of the degree of erythema, induration, and scale of a psoriatic lesion, at least 2 cm in diameter, selected as a target for response throughout the study period. The scores assigned were 0=clear, 1=almost clear, 2=mild clear, 3=moderate disease, 4=severe. Percent improvement from baseline was computed using the ratio of improvement from baseline to the baseline value.

    Time frame: From Baseline to Days 365 and 729

  4. Long-term Period: Mean Change From Baseline in the Short-form 36 (SF-36), Version 2, Domain and Component Scores at Days 365 and 729

    PCS=physical component score; MCS=mental component score. The SF-36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.

    Time frame: At Days 365 and 729 from baseline

  5. Long-term Period: Number of Participants Achieving A Reduction of At Least 0.3 Unit From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Days 365 and 729

    Per the HAQ-DI, participants assessed their own ability to perform the following tasks: dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity over a period by marking their responses on a questionnaire. Scoring of the HAQ-DI: 0=without any difficulty; 1=with some difficulty; 2=with much difficulty); and 3=unable to do. Greater score=greater disability. Responders with a \>= 0.3 unit decrease in index scores from baseline to days 365 and 729 were considered to be improved.

    Time frame: Days 365 and 729 from baseline

  6. Short-term Period: Number of Participants With Marked Abnormalities in Hematology

    LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormalities are laboratory measurements marked as abnormal, per predefined study criteria, at any study time point. Criteria: Hemoglobin \>3 g/dL decrease from pre-Rx value; hematocrit \<0.75\*pre-Rx value; erythrocytes \<0.75\*pre-Rx value; platelets \<0.67\*LLN (or, if pre-Rx value \<LLN, \<0.5\*pre-Rx value and \<100000/mm\^3) or \>1.5\*ULN.

    Time frame: From Baseline to Day 169

  7. Short-term Period: Number of Participants With Marked Abnormalities in Hematology (Continued)

    LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Laboratory measurements are marked as abnormal per predefined study criteria, at any study time point. Criteria for the data presented. Leukocytes \<0.75\*LLN or \>1.25\*ULN (or, if pre-Rx value \<LLN, \<0.8\*pre-Rx or \>ULN. If pre-Rx value \>ULN, \>1.2\*pre-Rx or \<LLN); neutrophils+bands (absolute) \<1.00\*10\^3 c/uL; lymphocytes (absolute) \<0.75\*10\^3 c/uL or \>7.50\*10\^3 c/uL; monocytes (absolute) \>2000/mm\^3; basophils (absolute) \>0.40\*10\^3 c/uL; eosinophils (absolute) \>0.75\*10\^3 c/uL.

    Time frame: From Baseline to Day 169

  8. Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry

    ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT) \>2\*ULN (if pre-Rx \>ULN, \>3\*pre-Rx); aspartate aminotransferase (AST), alanine transaminase (ALT) \>3\*ULN (if pre-Rx \>ULN, \>4\*pre-Rx); bilirubin (total) \>2\*ULN (if pre-Rx \>ULN, \>4\*pre-Rx); blood urea nitrogen (BUN) \>2\*pre-Rx; creatinine \>1.5\*pre-Rx.

    Time frame: Baseline to Day 169

  9. Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry (Continued)

    LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Sodium \<0.95\*LLN or \>1.05\*ULN (if pre-Rx\<LLN, \<0.95\*pre-Rx or \>ULN. If pre-Rx \>ULN,\>1.05\* pre-Rx or \<LLN); potassium, chloride \<0.9\*LLN or \>1.1\*ULN (if pre-Rx \<LLN, \<0.9\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.1\*pre-Rx or \<LLN); calcium \<0.8\*LLN or \>1.2\*ULN (if pre-Rx \<LLN,\<0.75\* pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.25\* pre-Rx or \<LLN); phosphorous \<0.75\*LLN or \>1.25\*ULN (if pre-Rx \<LLN, \<0.67\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.33\*pre-Rx or \<LLN.

    Time frame: Baseline to Day 169

  10. Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry (Continued)

    LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Glucose \<65 or \>220 mg/dL; glucose (fasting)\<0.8\*LLN or \>1.5\*ULN (if pre-Rx \<LLN, \<0.8\*pre-Rx or \>ULN. If pre-Rx \>ULN, t\>2.0\*pre-Rx or \<LLN). Protein (total) \<0.9\*LLN or \>1.1\*ULN (if pre-Rx \<LLN, \<0.9\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.1\*pre-Rx or \<LLN). Albumin \<0.9\*LLN (if pre-Rx \<LLN, \<0.75\* pre-Rx). Uric acid \>1.5\*ULN; if pre-Rx \>ULN or \>2\*pre-Rx value.

    Time frame: From Baseline to Day 169

  11. Short-term Period: Number of Participants With Marked Abnormalities in Urinalysis

    Pre-Rx=pretreatment. Criteria for marked abnormality: Protein, glucose, blood, leukocyte esterase, red blood cells (RBC), white blood cells (WBC) \>=2+ (or, if value \>=4, or if pre-Rx value=0 or 0.5, \>= 2\* or if pre-RX value =1, \>=3, or if pre-Rx =2 or 3, \>=4).

    Time frame: From Baseline to Day 169

  12. Short-term Period: Number of Participants Who Died and With SAEs, AEs, AEs Leading to Discontinuation, SAEs Leading to Discontinuation, Drug-related AEs, and Drug-related SAEs

    An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=possibly, probably, or certainly related to and of unknown relationship to study treatment.

    Time frame: From Baseline to Day 169

  13. Short-term Period: Number of Participants With an IGA Score of Clear or Almost Clear at Day 169

    Score indicates lesion induration, scaling, and erythema: 0 = clear (no signs of plaque psoriasis except for residual discoloration); 1 = almost clear (just perceptible erythema, no induration to very slightly elevated above normal skin levels, limited amount of very fine scaling); 2 = mild disease (mild erythema, mild induration, mainly fine scaling predominates); 3 = moderate disease (moderate erythema \[most plaques are red\], moderate induration and/or coarse scale predominates); 4=severe (severe erythema, marked to very marked elevation of lesions, coarse thick scale predominates).

    Time frame: At Day 169 from Baseline

  14. Short-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Day 169

    Target lesion score measures the degree of erythema, induration, and scale of a psoriatic lesion with a diameter of at least 2 cm, selected as a target for response throughout the study period. Scores: 0=clear, 1=almost clear, 2=mild clear, 3=moderate disease, 4=severe. Percent improvement from baseline was computed using the ratio of improvement from baseline to the baseline value.

    Time frame: At Day 169 from Baseline

  15. Short-term Period: Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies (Anti-Abatacept-C)

    Meso Scale Discovery electrochemiluminescence, a validated, sensitive immunoassay technique (anti-abatacept assay C) was used to measure serum levels of abatacept-specific antibodies against the whole molecule (both the CTLA4 and possibly immunoglobulin G portion \[anti-abatacept antibody\].

    Time frame: From Baseline to Day 169

  16. Short-term Period: Mean Change From Baseline in the Mental Component Summary Score as Measured by the Short-form 36 at Day 169

    PCS=physical component score; MCS=mental component score. The Short-form 36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.

    Time frame: At Day 169 from Baseline

  17. Short-term Period: Mean Serum Concentrations of Abatacept

    Abatacept was assayed using a validated enzyme linked immunosorbent assay method (ELISA). Serum concentration versus time data was analyzed in the descriptive pharmacokinetic (PK) analysis.

    Time frame: Days 1, 15, 29, 57, 85, 113, 141, and 169

  18. Short-term Period: Mean Serum Trough Concentrations (Cmin) of Abatacept

    Abatacept was assayed using a validated ELISA method. Cmin of abatacept was obtained from concentration versus time data.

    Time frame: Days 1, 15, 29, 57, 85, 113, 141, and 169

  19. Short-term Period: Population Pharmacokinetic (POPPK) Analysis of the Pharmacokinetic (PK) Parameters

    PK data: summaries of concentrations and concentration versus time plots were obtained. These data were to be used to develop a POPPK model using a nonlinear mixed-effects model. Prediction of PK data for each of the 3 abatacept treatment groups using POPPK methodology was not performed, because it would not provide any relevant information over the observed PK data.

    Time frame: Days 1, 15, 29, 57, 85, 113, 141, and 169

  20. Short-term Period: Mean Change From Baseline in Physical Component Summary Score as Measured by the Short-form 36 at Day 169

    PCS=physical component score; MCS=mental component score. The Short-form 36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.

    Time frame: At Day 169 from Baseline

  21. Short-term Period: Number of Participants Achieving a Reduction of At Least 0.3 Unit From Baseline in HAQ-DI Scores at Day 169

    The HAQ-DI assesses a participant's ability to perform the following tasks: dress/groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity over a period by marking their response on a questionnaire. Responses/scores range from: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=to unable to do. Higher total score=greater disability.

    Time frame: At Day 169 from Baseline

07

Results

Posted Nov 22, 2010

Participant flow

Short-term Period
Participant flow — Short-term Period
MilestoneAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Started43404542
Completed37344333
Not completed6629
Withdrew: Adverse event1213
Withdrew: Lack of efficacy3403
Withdrew: Participant not meeting study criteria0001
Withdrew: Participant withdrew consent2002
Withdrew: Pregnancy0010
Long-term Period
Participant flow — Long-term Period
MilestoneAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Started37344333
Completed0000
Not completed37344333
Withdrew: Adverse event2101
Withdrew: Lack of efficacy14101412
Withdrew: Lost to follow-up1200
Withdrew: Withdrawal by subject2200
Withdrew: No longer meets study criteria0100
Withdrew: Poor compliance/noncompliance0110
Withdrew: Administrative reason by sponsor17152618
Withdrew: Other1222

Outcome measures

PrimaryLong-term Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Drug-related AEs, AEs Leading to Discontinuation, and AEs of Interest

Presp=prespecified; acute= ≤1 hour after start of infusion; periinfusional= ≤24 hours after start of infusion. AE=any new unfavorable symptom or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=an unfavorable medical event that at any dose results in death, significant disability, drug dependency/abuse, hospitalization or prolonged hospitalization; is life-threatening, an important medical event, or a congenital anomaly/birth defect. Drug-related=possibly, probably, or certainly related and of unknown relationship to study drug.

Time frame:
From Day 169 to Day 729
Reported as:
Number · Participants
Long-term Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Drug-related AEs, AEs Leading to Discontinuation, and AEs of Interest
ParticipantsAll Treated Participants
Deaths0
SAEs20
Drug-related SAEs4
SAEs leading to discontinuation0
AEs123
Drug-related AEs58
AES leading to discontinuation4
AEs of Interest (AEI): Infections83
AEI: Malignancy2
AEI: Autoimmune disorders (presp)5
AEI: Infusion reactions (presp): Acute4
AEI: Infusion reactions (presp): Periinfusional11
SecondaryLong-term Period: Percentage of Participants Achieving American College of Rheumatology (ACR) 20, ACR 50, ACR 70, ACR 90 Responses at Days 365 and 729

An ACR 20 (50, 70, 90) responder was a participant whose counts for both tender and swollen joints was reduced by 20% (50%, 70%, 90%, respectively) or more from baseline and who had a reduction of 20% (50%, 70%, 90%, respectively) or more from baseline in 3 of the following assessments: participant's assessment of disease activity, participant's global assessment of disease activity, Investigators Global Response, participant's assessment of physical function by Health Assessment Questionnaire Disability Index, and Disease Activity Score 28 based on C-reactive protein.

Time frame:
At Days 365 and 729 from Baseline
Reported as:
Number · Percentage of participants
Long-term Period: Percentage of Participants Achieving American College of Rheumatology (ACR) 20, ACR 50, ACR 70, ACR 90 Responses at Days 365 and 729
Percentage of participantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
ACR 20, Day 365 (n=34, 29, 36, 32)50.0 (33.2 to 66.8)62.1 (44.4 to 79.7)61.1 (45.2 to 77.0)46.9 (29.6 to 64.2)
ACR 20, Day 729 (n=21, 18, 26, 18)81 (64.2 to 97.7)66.7 (44.9 to 88.4)65.4 (47.1 to 83.7)72.2 (51.5 to 92.9)
ACR 50, Day 365 (n=34, 29, 36, 32)23.5 (9.3 to 37.8)37.9 (20.3 to 55.6)33.3 (17.9 to 48.7)34.4 (17.9 to 50.8)
ACR 50, Day 729 (n=21, 18, 26, 18)57.1 (36.0 to 78.3)27.8 (7.1 to 48.5)42.3 (23.3 to 61.3)55.6 (32.6 to 78.5)
ACR 70, Day 365 (n=34, 29, 36, 32)5.9 (0.0 to 13.8)17.2 (3.5 to 31.01)13.9 (2.6 to 25.2)18.8 (5.2 to 32.2)
ACR 70, Day 729 (n=21, 18, 26, 18)23.8 (5.6 to 42.0)16.7 (0.0 to 33.9)23.1 (6.9 to 39.3)11.1 (0.0 to 25.6)
ACR 90, Day 365 (n=34, 29, 36, 32)0 (0.0 to 0.0)6.9 (0.0 to 16.1)5.6 (0.0 to 13.0)6.3 (0.0 to 14.6)
ACR 90, Day 729 (n=21, 18, 26, 18)0 (0.0 to 0.0)5.6 (0.0 to 16.1)11.5 (0.0 to 23.8)0 (0.0 to 0.0)
SecondaryLong-term Period: Number of Participants With an Investigators Global Assessment (IGA) Score of Clear or Almost Clear at Days 365 and 729

IGA score indicates lesion induration, scaling, and erythema: 0=clear (no signs of plaque psoriasis except for residual discoloration); 1=almost clear (just perceptible erythema, no induration to very slightly elevated above normal skin levels, limited amount of very fine scaling); 2=mild disease (mild erythema, mild induration, mainly fine scaling predominates); 3=moderate disease (moderate erythema \[most plaques are red\], moderate induration and/or coarse scale predominates); 4=severe (severe erythema, marked to very marked elevation of lesions, coarse thick scale predominates).

Time frame:
From Day 169 to Days 365 and 729
Reported as:
Number · Participants
Long-term Period: Number of Participants With an Investigators Global Assessment (IGA) Score of Clear or Almost Clear at Days 365 and 729
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Day 365 (n=30, 29, 34, 23)13101910
Day 729 (n=20, 17, 26, 18)107168
SecondaryLong-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Days 365 and 729

Target lesion score is a measurement of the degree of erythema, induration, and scale of a psoriatic lesion, at least 2 cm in diameter, selected as a target for response throughout the study period. The scores assigned were 0=clear, 1=almost clear, 2=mild clear, 3=moderate disease, 4=severe. Percent improvement from baseline was computed using the ratio of improvement from baseline to the baseline value.

Time frame:
From Baseline to Days 365 and 729
Reported as:
Mean · Percentage of change
Long-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Days 365 and 729
Percentage of changeAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Day 36527.51 ± 7.9241.97 ± 7.9020.32 ± 8.5933.82 ± 7.52
Day 72949.14 ± 9.1345.07 ± 7.9844.79 ± 9.0934.41 ± 8.98
SecondaryLong-term Period: Mean Change From Baseline in the Short-form 36 (SF-36), Version 2, Domain and Component Scores at Days 365 and 729

PCS=physical component score; MCS=mental component score. The SF-36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.

Time frame:
At Days 365 and 729 from baseline
Reported as:
Mean · Units on a scale
Long-term Period: Mean Change From Baseline in the Short-form 36 (SF-36), Version 2, Domain and Component Scores at Days 365 and 729
Units on a scaleAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Day 365 PCS (n=34, 32, 37,29)1.73 ± 1.107.59 ± 1.364.86 ± 1.673.59 ± 1.19
Day 365 MCS (n=34,32, 37,29)2.73 ± 1.601.07 ± 2.004.95 ± 2.104.40 ± 2.00
Day 729 PCS (n=20,18, 26,18)5.59 ± 1.437.97 ± 2.06.74 ± 1.954.45 ± 1.14
Day 729 MCS (n=20,18, 26,18)5.89 ± 1.84-0.17 ± 2.711.85 ± 2.114.35 ± 2.29
SecondaryLong-term Period: Number of Participants Achieving A Reduction of At Least 0.3 Unit From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Days 365 and 729

Per the HAQ-DI, participants assessed their own ability to perform the following tasks: dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity over a period by marking their responses on a questionnaire. Scoring of the HAQ-DI: 0=without any difficulty; 1=with some difficulty; 2=with much difficulty); and 3=unable to do. Greater score=greater disability. Responders with a \>= 0.3 unit decrease in index scores from baseline to days 365 and 729 were considered to be improved.

Time frame:
Days 365 and 729 from baseline
Reported as:
Number · Participants
Long-term Period: Number of Participants Achieving A Reduction of At Least 0.3 Unit From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Days 365 and 729
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Day 365 (n=3, 28, 32, 23)12161712
Day 729 (n=9, 11, 13, 10)9111310
SecondaryShort-term Period: Number of Participants With Marked Abnormalities in Hematology

LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormalities are laboratory measurements marked as abnormal, per predefined study criteria, at any study time point. Criteria: Hemoglobin \>3 g/dL decrease from pre-Rx value; hematocrit \<0.75\*pre-Rx value; erythrocytes \<0.75\*pre-Rx value; platelets \<0.67\*LLN (or, if pre-Rx value \<LLN, \<0.5\*pre-Rx value and \<100000/mm\^3) or \>1.5\*ULN.

Time frame:
From Baseline to Day 169
Reported as:
Number · Participants
Short-term Period: Number of Participants With Marked Abnormalities in Hematology
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Hemoglobin (n = 43, 40, 45, 41)0000
Hematocrit (n = 43, 40, 45, 41)0000
Erythrocytes (n = 43, 40, 45, 41)0000
Platelet count (n = 43, 40, 45, 41)0000
PrimaryShort-term Period: Number of Participants With ACR 20 Response at Day 169

An ACR 20 responder was a participant who had a reduction of 20% or more from baseline in scores for both tender and swollen joints and had a reduction from baseline of 20% or more in 3 out of the following 5 assessments: participant's assessment of disease activity, participant's global assessment of disease activity, investigator's global assessment of disease activity, participant's assessment of physical function by HAQ-DI, and Disease Activity Score 28-C reactive protein.

Time frame:
At Day 169 from Baseline
Reported as:
Number · Participants
Short-term Period: Number of Participants With ACR 20 Response at Day 169
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Short-term Period: Number of Participants With ACR 20 Response at Day 1691819158
Statistical analysis
  • Abatacept 30/10 vs Placebo · Cochran-Mantel-Haenszel · p = 0.022 (The p-value (two-sided) was based on Cochran-Mantel-Haenszel method (CMH) with stratification of baseline body surface area (BSA) affected by psoriasis.) · Difference: 22.9 · 95% CI 4.0 to 41.8Difference was based on CMH with stratification of baseline BSA affected by psoriasis.
  • Abatacept 10/10 vs Placebo · Cochran-Mantel-Haenszel · p = 0.006 (p-value (two-sided) was based on CMH with stratification of baseline BSA affected by psoriasis.) · Difference: 28.7 · 95% CI 9.4 to 48.0Difference was based on CMH with stratification of baseline BSA affected by psoriasis.
  • Abatacept 3/3 vs Placebo · Cochran-Mantel-Haenszel · p = 0.121 (p-value (2-sided) was based on CMH with stratification of baseline BSA affected by psoriasis.) · Difference: 14.6 · 95% CI -3.5 to 32.6Difference was based on CMH with stratification of baseline BSA affected by psoriasis.
SecondaryShort-term Period: Number of Participants With Marked Abnormalities in Hematology (Continued)

LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Laboratory measurements are marked as abnormal per predefined study criteria, at any study time point. Criteria for the data presented. Leukocytes \<0.75\*LLN or \>1.25\*ULN (or, if pre-Rx value \<LLN, \<0.8\*pre-Rx or \>ULN. If pre-Rx value \>ULN, \>1.2\*pre-Rx or \<LLN); neutrophils+bands (absolute) \<1.00\*10\^3 c/uL; lymphocytes (absolute) \<0.75\*10\^3 c/uL or \>7.50\*10\^3 c/uL; monocytes (absolute) \>2000/mm\^3; basophils (absolute) \>0.40\*10\^3 c/uL; eosinophils (absolute) \>0.75\*10\^3 c/uL.

Time frame:
From Baseline to Day 169
Reported as:
Number · Participants
Short-term Period: Number of Participants With Marked Abnormalities in Hematology (Continued)
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Leukocytes (n = 43, 40, 45, 41)0020
Neutrophils+bands (absolute) (n = 43, 40, 45, 41)0000
Lymphocytes (absolute) (n = 43, 40, 45, 41)2061
Monocytes (absolute) (n = 43, 40, 45, 41)0000
Basophils (absolute) (n = 43, 40, 45, 41)0000
Eosinophils (absolute) (n = 43, 40, 45, 41)1110
SecondaryShort-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry

ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT) \>2\*ULN (if pre-Rx \>ULN, \>3\*pre-Rx); aspartate aminotransferase (AST), alanine transaminase (ALT) \>3\*ULN (if pre-Rx \>ULN, \>4\*pre-Rx); bilirubin (total) \>2\*ULN (if pre-Rx \>ULN, \>4\*pre-Rx); blood urea nitrogen (BUN) \>2\*pre-Rx; creatinine \>1.5\*pre-Rx.

Time frame:
Baseline to Day 169
Reported as:
Number · Participants
Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
ALP (n = 43, 40, 45, 41)0000
AST (n = 43, 40, 45, 41)0000
ALT (n = 43, 40, 45, 41)1000
GGT (n = 43, 40, 45, 41)1000
Bilirubin (total) (n = 43, 40, 45, 41)0000
BUN (n = 43, 40, 45, 41)0000
Creatinine (n = 43, 40, 45, 41)0000
SecondaryShort-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry (Continued)

LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Sodium \<0.95\*LLN or \>1.05\*ULN (if pre-Rx\<LLN, \<0.95\*pre-Rx or \>ULN. If pre-Rx \>ULN,\>1.05\* pre-Rx or \<LLN); potassium, chloride \<0.9\*LLN or \>1.1\*ULN (if pre-Rx \<LLN, \<0.9\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.1\*pre-Rx or \<LLN); calcium \<0.8\*LLN or \>1.2\*ULN (if pre-Rx \<LLN,\<0.75\* pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.25\* pre-Rx or \<LLN); phosphorous \<0.75\*LLN or \>1.25\*ULN (if pre-Rx \<LLN, \<0.67\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.33\*pre-Rx or \<LLN.

Time frame:
Baseline to Day 169
Reported as:
Number · Participants
Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry (Continued)
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Sodium (n = 43, 40, 45, 41)0000
Potassium (n = 43, 40, 45, 41)0001
Chloride (n = 43, 40, 45, 41)0000
Calcium (total) (n = 43, 40, 45, 41)0000
Phosphorous , inorganic (n = 43, 40, 45, 41)0011
SecondaryShort-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry (Continued)

LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Glucose \<65 or \>220 mg/dL; glucose (fasting)\<0.8\*LLN or \>1.5\*ULN (if pre-Rx \<LLN, \<0.8\*pre-Rx or \>ULN. If pre-Rx \>ULN, t\>2.0\*pre-Rx or \<LLN). Protein (total) \<0.9\*LLN or \>1.1\*ULN (if pre-Rx \<LLN, \<0.9\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.1\*pre-Rx or \<LLN). Albumin \<0.9\*LLN (if pre-Rx \<LLN, \<0.75\* pre-Rx). Uric acid \>1.5\*ULN; if pre-Rx \>ULN or \>2\*pre-Rx value.

Time frame:
From Baseline to Day 169
Reported as:
Number · Participants
Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry (Continued)
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Glucose (n = 43, 40, 45, 41)1482
Glucose, fasting (n = 16, 12, 12, 15)0000
Protein (total) (n = 43, 40, 45, 41)0000
Albumin (n = 43, 40, 45, 41)0000
Uric acid (n = 43, 40, 45, 41)0000
SecondaryShort-term Period: Number of Participants With Marked Abnormalities in Urinalysis

Pre-Rx=pretreatment. Criteria for marked abnormality: Protein, glucose, blood, leukocyte esterase, red blood cells (RBC), white blood cells (WBC) \>=2+ (or, if value \>=4, or if pre-Rx value=0 or 0.5, \>= 2\* or if pre-RX value =1, \>=3, or if pre-Rx =2 or 3, \>=4).

Time frame:
From Baseline to Day 169
Reported as:
Number · Participants
Short-term Period: Number of Participants With Marked Abnormalities in Urinalysis
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Protein (n = 42, 37, 38, 40)0001
Glucose (n = 42, 37, 38, 40)0001
Blood (n = 42, 37, 38, 40)2232
Leukocyte esterase (n = 3, 7, 4, 5)0011
WBC (n = 6, 8, 8, 6)1133
RBC (n = 6, 7, 5, 6)3112
SecondaryShort-term Period: Number of Participants Who Died and With SAEs, AEs, AEs Leading to Discontinuation, SAEs Leading to Discontinuation, Drug-related AEs, and Drug-related SAEs

An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=possibly, probably, or certainly related to and of unknown relationship to study treatment.

Time frame:
From Baseline to Day 169
Reported as:
Number · Participants
Short-term Period: Number of Participants Who Died and With SAEs, AEs, AEs Leading to Discontinuation, SAEs Leading to Discontinuation, Drug-related AEs, and Drug-related SAEs
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Deaths0000
SAEs4201
AEs29313130
All AEs Leading to Discontinuation1213
All SAEs Leading to Discontinuation1000
Drug-related AEs1313127
Drug-related SAEs1100
SecondaryShort-term Period: Number of Participants With an IGA Score of Clear or Almost Clear at Day 169

Score indicates lesion induration, scaling, and erythema: 0 = clear (no signs of plaque psoriasis except for residual discoloration); 1 = almost clear (just perceptible erythema, no induration to very slightly elevated above normal skin levels, limited amount of very fine scaling); 2 = mild disease (mild erythema, mild induration, mainly fine scaling predominates); 3 = moderate disease (moderate erythema \[most plaques are red\], moderate induration and/or coarse scale predominates); 4=severe (severe erythema, marked to very marked elevation of lesions, coarse thick scale predominates).

Time frame:
At Day 169 from Baseline
Reported as:
Number · Participants
Short-term Period: Number of Participants With an IGA Score of Clear or Almost Clear at Day 169
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Short-term Period: Number of Participants With an IGA Score of Clear or Almost Clear at Day 1699101711
Statistical analysis
  • Abatacept 30/10 vs Placebo · Cochran-Mantel-Haenszel · Difference: -6.0 · 95% CI -23.0 to 11.0Difference and 95% confidence intervals (CI) was based on CMH with stratification of baseline BSA affected by psoriasis.
  • Abatacept 10/10 vs Placebo · Cochran-Mantel-Haenszel · Difference: -0.5 · 95% CI -18.0 to 17.1Difference and 95% CI was based on CMH with stratification of baseline BSA affected by psoriasis.
  • Abatacept 3/3 vs Placebo · Cochran-Mantel-Haenszel · Difference: 10.4 · 95% CI -7.6 to 28.5Difference and 95% CI was based on CMH with stratification of baseline BSA affected by psoriasis.
SecondaryShort-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Day 169

Target lesion score measures the degree of erythema, induration, and scale of a psoriatic lesion with a diameter of at least 2 cm, selected as a target for response throughout the study period. Scores: 0=clear, 1=almost clear, 2=mild clear, 3=moderate disease, 4=severe. Percent improvement from baseline was computed using the ratio of improvement from baseline to the baseline value.

Time frame:
At Day 169 from Baseline
Reported as:
Mean · Percentage of change
Short-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Day 169
Percentage of changeAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Short-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Day 16919.39 ± 9.1622.96 ± 9.4631.11 ± 8.980.63 ± 9.35
Statistical analysis
  • Abatacept 30/10 vs Placebo · ANCOVA · Mean difference (final values): 18.77 · 95% CI -7.02 to 44.56
  • Abatacept 10/10 vs Placebo · ANCOVA · Mean difference (final values): 22.34 · 95% CI -3.93 to 48.60
  • Abatacept 3/3 vs Placebo · ANCOVA · Mean difference (final values): 30.48 · 95% CI 4.82 to 56.15
SecondaryShort-term Period: Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies (Anti-Abatacept-C)

Meso Scale Discovery electrochemiluminescence, a validated, sensitive immunoassay technique (anti-abatacept assay C) was used to measure serum levels of abatacept-specific antibodies against the whole molecule (both the CTLA4 and possibly immunoglobulin G portion \[anti-abatacept antibody\].

Time frame:
From Baseline to Day 169
Reported as:
Number · Participants
Short-term Period: Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies (Anti-Abatacept-C)
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3
Short-term Period: Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies (Anti-Abatacept-C)102
SecondaryShort-term Period: Mean Change From Baseline in the Mental Component Summary Score as Measured by the Short-form 36 at Day 169

PCS=physical component score; MCS=mental component score. The Short-form 36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.

Time frame:
At Day 169 from Baseline
Reported as:
Mean · Units on a scale
Short-term Period: Mean Change From Baseline in the Mental Component Summary Score as Measured by the Short-form 36 at Day 169
Units on a scaleAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Short-term Period: Mean Change From Baseline in the Mental Component Summary Score as Measured by the Short-form 36 at Day 1694.50 ± 2.454.42 ± 2.503.16 ± 2.412.41 ± 2.47
Statistical analysis
  • Abatacept 30/10 vs Placebo · ANCOVA · Mean difference (net): 2.08 · 95% CI -4.79 to 8.96ANCOVA model with treatment as factor and baseline value as covariate was used for the analysis.
  • Abatacept 10/10 vs Placebo · ANCOVA · Mean difference (net): 2.01 · 95% CI -4.94 to 8.95ANCOVA model with treatment as factor and baseline value as covariate was used for the analysis.
  • Abatacept 3/3 vs Placebo · ANCOVA · Mean difference (net): 0.75 · 95% CI -6.08 to 7.58ANCOVA model with treatment as factor and baseline value as covariate was used for the analysis.
SecondaryShort-term Period: Mean Serum Concentrations of Abatacept

Abatacept was assayed using a validated enzyme linked immunosorbent assay method (ELISA). Serum concentration versus time data was analyzed in the descriptive pharmacokinetic (PK) analysis.

Time frame:
Days 1, 15, 29, 57, 85, 113, 141, and 169
Reported as:
Mean · µg/mL
Short-term Period: Mean Serum Concentrations of Abatacept
µg/mLAbatacept 30/10Abatacept 10/10Abatacept 3/3
Day 1 (n= 13, 13, 44)0 ± 00.01 ± 0.010 ± 0
Day 15 (n= 43, 38, 42)119.99 ± 35.3048.29 ± 17.9614.28 ± 7.67
Day 29 (n= 41, 39, 43)186.82 ± 62.4949.70 ± 16.7916.20 ± 4.86
Day 57 (n= 40, 39, 44)58.55 ± 26.0925.75 ± 9.6710.42 ± 5.75
Day 85 (n= 37, 35, 41)39.00 ± 19.3726.29 ± 10.598.73 ± 3.26
Day 113 ( n= 35, 33, 43)36.30 ± 19.9432.69 ± 14.088.85 ± 5.01
Day 141 (n= 35, 34, 42)26.70 ± 9.2425.78 ± 9.747.66 ± 3.13
Day 169 (n= 36, 42, 34)28.93 ± 11.2926.34 ± 10.759.29 ± 5.23
SecondaryShort-term Period: Mean Serum Trough Concentrations (Cmin) of Abatacept

Abatacept was assayed using a validated ELISA method. Cmin of abatacept was obtained from concentration versus time data.

Time frame:
Days 1, 15, 29, 57, 85, 113, 141, and 169
Reported as:
Geometric mean · µg/mL
Short-term Period: Mean Serum Trough Concentrations (Cmin) of Abatacept
µg/mLAbatacept 30/10Abatacept 10/10Abatacept 3/3
Day 15 (n= 43, 38, 43)115.35 (70.65 to 236.39)45.10 (21.27 to 95.96)12.81 (4.25 to 39.81)
Day 29 (n= 41, 39, 43)176.22 (68.45 to 373.07)46.86 (21.23 to 87.55)15.43 (4.99 to 28.15)
Day 57 (n= 40, 39, 44)53.08 (11.21 to 151.10)23.88 (8.18 to 50.84)9.03 (2.53 to 33.88)
Day 85 (n= 37, 35, 41)33.09 (1.87 to 94.46)24.36 (10.47 to 55.13)8.15 (2.97 to 16.01)
Day 113 (n= 35, 33, 43)31.50 (8.30 to 78.91)29.60 (6.66 to 71.21)7.56 (2.14 to 27.82)
Day 141 (n= 35, 34, 42)25.02 (10.77 to 43.31)23.62 (7.24 to 45.66)6.91 (1.50 to 14.32)
Day 169 (n= 36, 34, 42)26.65 (10.05 to 53.77)24.33 (11.65 to 50.31)7.84 (1.68 to 28.85)
SecondaryShort-term Period: Population Pharmacokinetic (POPPK) Analysis of the Pharmacokinetic (PK) Parameters

PK data: summaries of concentrations and concentration versus time plots were obtained. These data were to be used to develop a POPPK model using a nonlinear mixed-effects model. Prediction of PK data for each of the 3 abatacept treatment groups using POPPK methodology was not performed, because it would not provide any relevant information over the observed PK data.

Time frame:
Days 1, 15, 29, 57, 85, 113, 141, and 169

No measurements were reported for this outcome.

SecondaryShort-term Period: Mean Change From Baseline in Physical Component Summary Score as Measured by the Short-form 36 at Day 169

PCS=physical component score; MCS=mental component score. The Short-form 36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.

Time frame:
At Day 169 from Baseline
Reported as:
Mean · Units on a scale
Short-term Period: Mean Change From Baseline in Physical Component Summary Score as Measured by the Short-form 36 at Day 169
Units on a scaleAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Short-term Period: Mean Change From Baseline in Physical Component Summary Score as Measured by the Short-form 36 at Day 1697.30 ± 1.859.27 ± 1.916.32 ± 1.820.15 ± 1.87
Statistical analysis
  • Abatacept 30/10 vs Placebo · ANCOVA · Mean difference (net): 7.15 · 95% CI 1.97 to 12.33Analysis of covariance (ANCOVA) model with treatment as factor and baseline value as covariate was used for the analysis.
  • Abatacept 10/10 vs Placebo · ANCOVA · Mean difference (net): 9.12 · 95% CI 3.83 to 14.41ANCOVA model with treatment as factor and baseline value as covariate was used for the analysis
  • Abatacept 3/3 vs Placebo · ANCOVA · Mean difference (net): 6.17 · 95% CI 1.01 to 11.32ANCOVA model with treatment as factor and baseline value as covariate was used for the analysis.
SecondaryShort-term Period: Number of Participants Achieving a Reduction of At Least 0.3 Unit From Baseline in HAQ-DI Scores at Day 169

The HAQ-DI assesses a participant's ability to perform the following tasks: dress/groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity over a period by marking their response on a questionnaire. Responses/scores range from: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=to unable to do. Higher total score=greater disability.

Time frame:
At Day 169 from Baseline
Reported as:
Number · Participants
Short-term Period: Number of Participants Achieving a Reduction of At Least 0.3 Unit From Baseline in HAQ-DI Scores at Day 169
ParticipantsAbatacept 30/10Abatacept 10/10Abatacept 3/3Placebo
Short-term Period: Number of Participants Achieving a Reduction of At Least 0.3 Unit From Baseline in HAQ-DI Scores at Day 1691518168
Statistical analysis
  • Abatacept 30/10 vs Placebo · Cochran-Mantel-Haenszel · Difference: 16.0 · 95% CI -2.5 to 34.5Difference and 95% CI was based on CMH with stratification of baseline BSA affected by psoriasis.
  • Abatacept 10/10 vs Placebo · Cochran-Mantel-Haenszel · Difference: 26.1 · 95% CI 6.8 to 45.5Difference and 95% CI was based on CMH with stratification of baseline BSA affected by psoriasis.
  • Abatacept 3/3 vs Placebo · Cochran-Mantel-Haenszel · Difference: 16.6 · 95% CI -1.8 to 34.9Difference and 95% CI was based on CMH with stratification of baseline BSA affected by psoriasis.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept 10/10 (Short-term Period)—2/40 (5%)16/40 (40%)
Abatacept 3/3 (Short-term Period)—1/45 (2.2%)15/45 (33.3%)
Abatacept 30/10 (Short-term Period)—4/43 (9.3%)16/43 (37.2%)
Abatacept (Long-term Period)—20/147 (13.6%)73/147 (49.7%)
Placebo (Short-term Period)—1/42 (2.4%)19/42 (45.2%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventAbatacept 10/10 (Short-term Period)Abatacept 3/3 (Short-term Period)Abatacept 30/10 (Short-term Period)Abatacept (Long-term Period)Placebo (Short-term Period)
GastroenteritisInfections and infestations1/400/450/431/1470/42
DizzinessNervous system disorders1/400/450/430/1470/42
Personality disorderPsychiatric disorders0/400/450/431/1471/42
Family stressSocial circumstances0/400/450/431/1471/42
Cholecystitis acuteHepatobiliary disorders0/400/451/430/1470/42
OsteomyelitisInfections and infestations0/400/451/430/1470/42
OverdoseInjury, poisoning and procedural complications0/400/451/430/1470/42
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/400/451/430/1470/42
OsteoarthritisMusculoskeletal and connective tissue disorders0/401/450/433/1470/42
Psoriatic arthropathyMusculoskeletal and connective tissue disorders0/401/450/430/1470/42
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAbatacept 10/10 (Short-term Period)Abatacept 3/3 (Short-term Period)Abatacept 30/10 (Short-term Period)Abatacept (Long-term Period)Placebo (Short-term Period)
NasopharyngitisInfections and infestations4/405/454/4333/1474/42
Upper respiratory tract infectionInfections and infestations1/403/452/4316/1472/42
HeadacheNervous system disorders1/403/454/439/1474/42
BronchitisInfections and infestations1/400/453/4313/1471/42
SinusitisInfections and infestations2/401/452/4312/1472/42
DiarrhoeaGastrointestinal disorders3/400/450/438/1472/42
FatigueGeneral disorders3/401/451/433/1471/42
HypertensionVascular disorders3/401/451/437/1471/42
NauseaGastrointestinal disorders2/401/452/436/1473/42
CoughRespiratory, thoracic and mediastinal disorders0/401/453/438/1471/42

Baseline characteristics

Age Continuous
Age Continuous(years)Abatacept 30/10Abatacept 10/10Abatacept 3/3PlaceboTotal
Median54.0 (29.0 to 69.0)51.5 (26.0 to 73.0)51.0 (29.0 to 72.0)53.0 (30.0 to 82.0)52.0 (26.0 to 82.0)
Sex: Female, Male
Sex: Female, Male(Participants)Abatacept 30/10Abatacept 10/10Abatacept 3/3PlaceboTotal
Female2314231979
Male2026222391
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Abatacept 30/10Abatacept 10/10Abatacept 3/3PlaceboTotal
White43384441166
Asian02103
Pacific00011
Weight
Weight(kilograms)Abatacept 30/10Abatacept 10/10Abatacept 3/3PlaceboTotal
Mean92.9 ± 21.385.0 ± 17.985.0 ± 19.196.0 ± 19.489.7 ± 19.9
08

Study locations

44 sites
  • Rheumatology Associates Of North Alabama
    Huntsville, Alabama 35801, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Stanford University School Of Medicine
    Palo Alto, California 94304, United States
  • Boling Clinical Trials
    Upland, California 91786, United States
  • Joao Nascimento
    Bridgeport, Connecticut 06606, United States
  • New England Research Associates, Llc
    Trumbull, Connecticut 06611, United States
  • Sarasota Arthritis Research Center
    Sarasota, Florida 34239, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01610, United States
  • Justus Fiechtner, Md, Mph
    Lansing, Michigan 48910, United States
  • St. Paul Rheumatology P.A.
    Eagan, Minnesota 55121, United States
  • Midwest Arthritis Center
    Kalamazoo, Minnesota 49048, United States
  • Arthritis Clinic & Carolina Bone & Joint, Pa
    Charlotte, North Carolina 28210, United States
  • Deaconess Hospital
    Cincinnati, Ohio 45219, United States
  • Health Research Of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Rheumatic Disease Associates, Ltd.
    Willow Grove, Pennsylvania 19090, United States
  • Chase, Walter F.
    Austin, Texas 78705, United States
  • Seattle Rheumatology Associates
    Seattle, Washington 98104, United States
  • Arthritis Northwest
    Spokane, Washington 99204, United States
  • Local Institution
    Capital Federal, Buenos Aires 1015, Argentina
  • Local Institution
    Rosario, Santa Fe 2000, Argentina
  • Local Institution
    Santa Fe, 3000, Argentina
  • Local Institution
    Cairns, Queensland 4872, Australia
  • Local Institution
    Maroochydore, Queensland 4558, Australia
  • Local Institution
    Fitzroy, Melbourne, Victoria 3065, Australia
  • Local Institution
    Hasselt, 3500, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    St. John'S, Newfoundland and Labrador A1B 3E1, Canada
  • Local Institution
    Montreal, Quebec H2L 1S6, Canada
  • Local Institution
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • Local Institution
    Quebec, G1W 4R4, Canada
  • Local Institution
    Chambray Les Tours, 37170, France
  • Local Institution
    Lille, 59037, France
  • Local Institution
    Montpellier Cedex 5, 34295, France
  • Local Institution
    Frankfurt/Main, 60590, Germany
  • Local Institution
    Hamburg, 22081, Germany
  • Local Institution
    Hildesheim, 31134, Germany
  • Local Institution
    Napoli, 80131, Italy
  • Local Institution
    Potenza, 85100, Italy
  • Local Institution
    Reggio Emilia, 42100, Italy
  • Local Institution
    Amsterdam, 1105 AZ, Netherlands
  • Local Institution
    Lillehammer, 2609, Norway
  • Local Institution
    Panorama, Western Cape 7500, South Africa
  • Local Institution
    A Coruna, 15006, Spain
09

References and documents

Publications

  • Ostergaard M, Bird P, Pachai C, Du S, Wu C, Landis J, Fuerst T, Ahmad HA, Connolly SE, Conaghan PG. Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis. Rheumatology (Oxford). 2022 Nov 2;61(11):4305-4313. doi: 10.1093/rheumatology/keac073. PubMed 35137002 ↗
  • Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, Wollenhaupt J, Bahary O, Becker JC, Kelly S, Sigal L, Teng J, Gladman D. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011 Apr;63(4):939-48. doi: 10.1002/art.30176. PubMed 21128258 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Dec 2008 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2007
First posted
Sep 24, 2007
Start
Nov 2007
Primary completionActual
Dec 2008
CompletionActual
May 2011
Results first posted
Nov 22, 2010
Last update
Aug 1, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00534313
Responsible party
Sponsor
First posted
Sep 24, 2007
Start date
Nov 2007
Primary completion
Dec 2008
Completion
May 2011
Results posted
Nov 22, 2010
Last update
Aug 1, 2012

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion